About Foresight Diagnostics
Foresight Diagnostics is a Healthcare company based in Aurora (United States) founded in 2020 by Ash Alizadeh, David Kurtz, Jake Chabon, and Maximilian Diehn, and was acquired by Natera in December 2025. Minimally invasive liquid biopsy tests for cancer detection are developed. Foresight Diagnostics has raised $104.25 million across 3 funding rounds from investors including Natera, Pear VC and Foresite Capital. Its chief executive, as recorded, is Jake Chabon. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Guardant Health, GRAIL and Natera; 3 of its 3 listed competitors have raised funding.
Company details
Foresight Diagnostics was founded in 2020 and is based in Aurora, United States. A liquid biopsy testing platform is developed using PhasED-Seq technology to detect ctDNA levels in patients with solid tumors and hematologic malignancies. Operations focus on minimally invasive diagnostics within the biotechnology sector, enabling early cancer detection through non-invasive methods. The platform supports clinical applications for tumor monitoring and treatment response assessment.
- Headquarters Aurora, United States
- Founders Ash Alizadeh, David Kurtz, Jake Chabon, Maximilian Diehn
- Stage Acquired
- SectorsHealthcare
- Website foresight-dx.com
- Social LinkedIn X
- Acquired by Natera (Dec 2025)
Funding Insights of Foresight Diagnostics
Foresight Diagnostics has successfully raised a total of $104.25M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $33 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $104.25M
- Total Rounds 3
- Last Round Series B — $33M
- First Round $12.5M
(Jun 2021)
- Investors Count 7
All 3 funding rounds of Foresight Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $33M | Series B | – | Foresite Capital, Civilization Ventures | – |
| Apr 2023 | $58.75M | Series B | – | Foresite Capital | |
| Jun 2021 | $12.5M | Series A | – | Civilization Ventures, Bluebird Ventures |
8 investors in total: 8 institutional.
Investors in Foresight Diagnostics
Foresight Diagnostics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Natera, Pear VC and Foresite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
Bluebird Ventures is engaged in life sciences venture capital investment. | 2019 | bluebirdvc.com | Palo Alto, United States | |
Seed & early stage VC firm investing the US | 2013 | pear.vc | San Francisco, United States | |
Agent Capital is focused on healthcare venture capital investments. | agentcapital.com | Waltham, United States | ||
| cuvcfund.com | ||||
Stanford Cardinal is operated as the athletics division of Stanford University. | gostanford.com | Stanford, United States | ||
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | natera.com | Redwood City, United States |
Investor details for Foresight Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Foresight Diagnostics
36 people are tracked at Foresight Diagnostics (15 in leadership, 6 in board & advisors, 15 in team).
| Name | Role | Group |
|---|---|---|
Ash Alizadeh | Co-Founder | Leadership |
David Kurtz | Co-Founder | Leadership |
Jake Chabon | Co-Founder & CEO | Leadership |
Maximilian Diehn | Co-Founder | Leadership |
Nathan Valverde | Director Of Business Development | Leadership |
Bernice Adams | Director Of Business Development | Leadership |
Brittin Davis | VP, Business & Laboratory Operations | Leadership |
Laura Hyland | Senior Director, Regulated Assay Development | Leadership |
Suzanne Andrews | Senior Executive Assistant To The CEO And Board Of Directors | Leadership |
Sandy Close | COO | Leadership |
John Truesdell | Chief Business Officer | Leadership |
Wendy Yee | Vp, Product Software | Leadership |
Stephen Saye | Director Of Reagent Manufacturing | Leadership |
Ruben Gutierrez | Senior Vice President And General Counsel | Leadership |
McKenzie Carlisle | Senior Director, Regulatory Operations & Compliance | Leadership |
Stanley Lapidus | Advisor | Board & advisors |
Christopher R. Flowers | Scientific Advisor | Board & advisors |
Mark Lee | Board Member | Board & advisors |
Shahram Seyedin-Noor | Board Member | Board & advisors |
Jeff Bird | Board Member | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Foresight Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Foresight Diagnostics
4 dated milestones of Foresight Diagnostics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Foresight Diagnostics is founded.
- Funding First funding round of $12.5M.
- Funding Latest funding round, Series B, of $33.0M.
- Exit Acquired by Natera.
Competitors of Foresight Diagnostics
Foresight Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of Foresight Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Foresight Diagnostics
The website of Foresight Diagnostics (foresight-dx.com) receives about 6.7K visits a month.
- Monthly visits6.7K
▼ 33.7% vs previous month
Websites whose visitors overlap most with Foresight Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrialsarena.com | 100% | #257,942 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Foresight Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Foresight Diagnostics
Complete news archive for Foresight Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Foresight Diagnostics
Foresight Diagnostics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Foresight Diagnostics is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
Jake Chabon is the CEO of Foresight Diagnostics, as recorded in our data. They have also founded this company.
Foresight Diagnostics is a funded company, having raised a total of $104.25M across 3 funding rounds to date. The company's 1st funding round was a Series A of $12.5M, raised on Jun 2021.
Foresight Diagnostics was founded in 2020 and is based in Aurora, United States. A liquid biopsy testing platform is developed using PhasED-Seq technology to detect ctDNA levels in patients with solid tumors and hematologic malignancies. Operations focus on minimally invasive diagnostics within the biotechnology sector, enabling early cancer detection through non-invasive methods. The platform supports clinical applications for tumor monitoring and treatment response assessment.
Foresight Diagnostics's top competitors include Guardant Health, GRAIL and Natera.
Foresight Diagnostics has 8 investors. Key investors include Natera, Pear VC, Foresite Capital, Civilization Ventures, and Bluebird Ventures.
Yes. Foresight Diagnostics was acquired by Natera in December 2025.